We are live on ! Find out more
LSB

LakeShore Biopharma
LSB

Delisted

LSB was delisted on the 19th of September, 2025.

Back to rankings

7 hedge funds and large institutions have $2.23M invested in LakeShore Biopharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.02% less ownership

Funds ownership: 2.72% → 1.69% (-1%)

33% less capital invested

Capital invested by funds: $3.34M → $2.23M (-$1.11M)

36% less funds holding

Funds holding: 11 → 7 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
-4
Holders Change %
-36.36%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$25.6K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$910K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$103K
3
Fidelity International
Fidelity International
Bermuda
-$61.1K
4
Citadel Advisors
Citadel Advisors
Florida
-$26.4K
5
OCM
Ovata Capital Management
Hong Kong
-$10.2K

LSB Hedge Fund Activity: Q3 2024 in Review

7 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q3 2024, worth a combined $2.23M — down 33% from $3.34M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of LSB and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $25.6K. The largest seller was OrbiMed, exiting entirely with an estimated $910K sold.

  • 7 institutional investors held LakeShore Biopharma (LSB) as of Q3 2024, down from 11 in Q2 2024.
  • Funds reported $2.23M of LakeShore Biopharma stock for Q3 2024, down 33% quarter-over-quarter.
  • 1 fund opened new LakeShore Biopharma positions in Q3 2024 and 5 closed out, a net change of -4 holders.
  • The largest LakeShore Biopharma buyer in Q3 2024 was UBS Group, an estimated $25.6K added.
  • The largest LakeShore Biopharma seller in Q3 2024 was OrbiMed, an estimated $910K sold.

Based on aggregated 13F filings for Q3 2024.